The artificial blood vessel approved by the FDA arouses concern
When the Biotechnological company Humacyte designed a study to see if its blood vessel raised in the laboratory worked, she decided to measure if the blood flowed freely through the high -tech tube 30 days after it was implanted in a person.With the passage of those days, some of the 54 patients in the study came across trouble. The doctors have lost the trace of one. Four are dead. Four others had an amputated limb, including one who developed a clot and an infection in the artificial ship records, Food and Drug Administration Records.Humacyte, which is exchanged on Nasdaq, considered all those patients as proof of success in talks with investors and in an article on Jama surgery.At the FDA, however, scientists counted the dead, amputations and the case lost as failures, show the register...










